Scarica l'app Stockscreener
571.44
0.02%
0.11
Dopo l'orario di chiusura:
580.50
9.06
+1.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Taub of Madrigal Pharmaceuticals sells $10.3 million in stock By Investing.com - Investing.com UK
Madrigal Pharmaceuticals expands workforce with new equity grants to staff - MSN
Madrigal Pharmaceuticals Appoints New Chief Accounting Officer - TradingView
Key facts: B. Riley Raises Madrigal Price Target to $670; Directors File Form 144 - TradingView
Madrigal Pharmaceuticals (MDGL) Sees Price Target Increase By B. - GuruFocus
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data - Insider Monkey
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Madrigal Pharmaceuticals Expands Workforce With New Equity Grants to Staff - MyChesCo
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Two-Year Rezdiffra Cirrhosis Data - Sahm
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockCash Flow Trends & Exceptional Capital Investment - earlytimes.in
Madrigal Pharmaceuticals (MDGL): Rezdiffra’s Strong Launch Spurs Rethink of Blockbuster Potential and Current Valuation - Yahoo Finance
Why analysts remain bullish on Madrigal Pharmaceuticals Inc. stockGap Down & Entry and Exit Point Strategies - Newser
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $2,413,412.82 in Stock - MarketBeat
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing - marketscreener.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock By Investing.com - Investing.com Australia
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potentialPrice Action & Stepwise Entry/Exit Trade Alerts - Newser
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Lobbying Update: $30,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Schroder Investment Management Group Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by New York State Common Retirement Fund - MarketBeat
Can Madrigal Pharmaceuticals Inc. (YDO1) stock double in coming yearsWall Street Watch & Stock Portfolio Risk Control - Newser
Legal & General Group Plc Increases Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How Madrigal Pharmaceuticals Inc. (YDO1) stock valuation compares with sectorWeekly Trade Review & Real-Time Buy Signal Notifications - Newser
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWeekly Investment Recap & Fast Gain Stock Trading Tips - Newser
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth story2025 Technical Patterns & Free Community Consensus Stock Picks - Newser
Madrigal Pharma EVP Dier sells $2.4m in MDGL stock - Investing.com
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,413,416, According to a Recent SEC Filing - marketscreener.com
MDGL: Billion-dollar run rate, expanding prescriber base, and robust pipeline drive long-term growth - TradingView
Russell Investments Group Ltd. Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikesJuly 2025 Pullbacks & High Accuracy Investment Signals - Newser
Madrigal Pharmaceuticals (MDGL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug - Insider Monkey
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Swiss National Bank - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Franklin Resources Inc. - MarketBeat
Madrigal Pharmaceuticals Inc (YDO1.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Why (MDGL) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Groupama Asset Managment Purchases 7,439 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Creative Planning Lowers Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by American Century Companies Inc. - MarketBeat
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN
Why Madrigal Pharmaceuticals (MDGL) Is Up 8.9% After Positive Two-Year Rezdiffra Data in MASH Cirrhosis - Sahm
Is Madrigal Pharmaceuticals Still Attractively Priced After 42.6% Surge on R&D Progress? - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Why retail traders accumulate Madrigal Pharmaceuticals Inc. (YDO1) stock2025 Support & Resistance & Precise Swing Trade Alerts - moha.gov.vn
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Is Madrigal Pharmaceuticals Inc. stock vulnerable to regulatory risks2025 Valuation Update & Weekly Sector Rotation Insights - BỘ NỘI VỤ
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):